Molecular biomarkers of Alzheimer's disease: progress and prospects

Tammaryn Lashley, Jonathan M Schott, Philip Weston, Christina E Murray, Henny Wellington, Ashvini Keshavan, Sandrine C Foti, Martha Foiani, Jamie Toombs, Jonathan D Rohrer, Amanda Heslegrave, Henrik Zetterberg, Tammaryn Lashley, Jonathan M Schott, Philip Weston, Christina E Murray, Henny Wellington, Ashvini Keshavan, Sandrine C Foti, Martha Foiani, Jamie Toombs, Jonathan D Rohrer, Amanda Heslegrave, Henrik Zetterberg

Abstract

The neurodegenerative disorder Alzheimer's disease is characterised by the formation of β-amyloid plaques and neurofibrillary tangles in the brain parenchyma, which cause synapse and neuronal loss. This leads to clinical symptoms, such as progressive memory deficits. Clinically, these pathological changes can be detected in the cerebrospinal fluid and with brain imaging, although reliable blood tests for plaque and tangle pathologies remain to be developed. Plaques and tangles often co-exist with other brain pathologies, including aggregates of transactive response DNA-binding protein 43 and Lewy bodies, but the extent to which these contribute to the severity of Alzheimer's disease is currently unknown. In this 'At a glance' article and poster, we summarise the molecular biomarkers that are being developed to detect Alzheimer's disease and its related pathologies. We also highlight the biomarkers that are currently in clinical use and include a critical appraisal of the challenges associated with applying these biomarkers for diagnostic and prognostic purposes of Alzheimer's disease and related neurodegenerative disorders, also in their prodromal clinical phases.

Keywords: Alzheimer's disease; Amyloid; Biomarkers; Blood; Cerebrospinal fluid; Neurofilament; Neurogranin; Plasma; Serum; Tau.

Conflict of interest statement

Competing interestsThe authors declare no competing or financial interests.

© 2018. Published by The Company of Biologists Ltd.

Figures

https://www.ncbi.nlm.nih.gov/pmc/articles/instance/5992610/bin/dmm-11-031781-g1.jpg

References

    1. Abdelnour C., van Steenoven I., Londos E., Blanc F., Auestad B., Kramberger M. G., Zetterberg H., Mollenhauer B., Boada M. and Aarsland D. (2016). Alzheimer's disease cerebrospinal fluid biomarkers predict cognitive decline in lewy body dementia. Mov. Disord. 31, 1203-1208. 10.1002/mds.26668
    1. Andreasson U., Blennow K. and Zetterberg H. (2016). Update on ultrasensitive technologies to facilitate research on blood biomarkers for central nervous system disorders. Alzheimers Dement. 3, 98-102. 10.1016/j.dadm.2016.05.005
    1. Barbour R., Kling K., Anderson J. P., Banducci K., Cole T., Diep L., Fox M., Goldstein J. M., Soriano F., Seubert P. et al. (2008). Red blood cells are the major source of alpha-synuclein in blood. Neurodegener. Dis. 5, 55-59. 10.1159/000112832
    1. Bateman R. J., Xiong C., Benzinger T. L., Fagan A. M., Goate A., Fox N. C., Marcus D. S., Cairns N. J., Xie X., Blazey T. M. et al. (2012). Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N. Engl. J. Med. 367, 795-804. 10.1056/NEJMoa1202753
    1. Bereczki E., Francis P. T., Howlett D., Pereira J. B., Höglund K., Bogstedt A., Cedazo-Minguez A., Baek J.-H., Hortobágyi T., Attems J. et al. (2016). Synaptic proteins predict cognitive decline in Alzheimer's disease and Lewy body dementia. Alzheimers Dement. 12, 1149-1158. 10.1016/j.jalz.2016.04.005
    1. Blennow K., de Leon M. J. and Zetterberg H. (2006). Alzheimer's disease. Lancet 368, 387-403. 10.1016/S0140-6736(06)69113-7
    1. Blennow K., Hampel H., Weiner M. and Zetterberg H. (2010). Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat. Rev. Neurol. 6, 131-144. 10.1038/nrneurol.2010.4
    1. Blennow K., Mattsson N., Schöll M., Hansson O. and Zetterberg H. (2015). Amyloid biomarkers in Alzheimer's disease. Trends Pharmacol. Sci. 36, 297-309. 10.1016/j.tips.2015.03.002
    1. Brinkmalm A., Brinkmalm G., Honer W. G., Frölich L., Hausner L., Minthon L., Hansson O., Wallin A., Zetterberg H., Blennow K. et al. (2014). SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer's disease. Mol. Neurodegener. 9, 53 10.1186/1750-1326-9-53
    1. Buerger K., Ewers M., Pirttila T., Zinkowski R., Alafuzoff I., Teipel S. J., DeBernardis J., Kerkman D., McCulloch C., Soininen H. et al. (2006). CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain 129, 3035-3041. 10.1093/brain/awl269
    1. Burnham S. C., Rowe C. C., Baker D., Bush A. I., Doecke J. D., Faux N. G., Laws S. M., Martins R. N., Maruff P., Macaulay S. L. et al. (2016). Predicting Alzheimer disease from a blood-based biomarker profile: a 54-month follow-up. Neurology 87, 1093-1101. 10.1212/WNL.0000000000003094
    1. Chhatwal J. P., Schultz A. P., Marshall G. A., Boot B., Gomez-Isla T., Dumurgier J., LaPoint M., Scherzer C., Roe A. D., Hyman B. T. et al. (2016). Temporal T807 binding correlates with CSF tau and phospho-tau in normal elderly. Neurology 87, 920-926. 10.1212/WNL.0000000000003050
    1. Cirrito J. R., Yamada K. A., Finn M. B., Sloviter R. S., Bales K. R., May P. C., Schoepp D. D., Paul S. M., Mennerick S. and Holtzman D. M. (2005). Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron 48, 913-922. 10.1016/j.neuron.2005.10.028
    1. Corrêa J. D., Starling D., Teixeira A. L., Caramelli P. and Silva T. A. (2011). Chemokines in CSF of Alzheimer's disease patients. Arq. Neuropsiquiatr. 69, 455-459. 10.1590/S0004-282X2011000400009
    1. Craig-Schapiro R., Perrin R. J., Roe C. M., Xiong C., Carter D., Cairns N. J., Mintun M. A., Peskind E. R., Li G., Galasko D. R. et al. (2010). YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease. Biol. Psychiatry 68, 903-912. 10.1016/j.biopsych.2010.08.025
    1. de Jong D., Jansen R. W. M. M., Pijnenburg Y. A. L., van Geel W. J. A., Borm G. F., Kremer H. P. H. and Verbeek M. M. (2007). CSF neurofilament proteins in the differential diagnosis of dementia. J. Neurol. Neurosurg. Psychiatry 78, 936-938. 10.1136/jnnp.2006.107326
    1. De Vos A., Jacobs D., Struyfs H., Fransen E., Andersson K., Portelius E., Andreasson U., De Surgeloose D., Hernalsteen D., Sleegers K. et al. (2015). C-terminal neurogranin is increased in cerebrospinal fluid but unchanged in plasma in Alzheimer's disease. Alzheimers Dement. 11, 1461-1469. 10.1016/j.jalz.2015.05.012
    1. Dubois B., Feldman H. H., Jacova C., Hampel H., Molinuevo J. L., Blennow K., DeKosky S. T., Gauthier S., Selkoe D., Bateman R. et al. (2014). Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol. 13, 614-629. 10.1016/S1474-4422(14)70090-0
    1. Fairfoul G., McGuire L. I., Pal S., Ironside J. W., Neumann J., Christie S., Joachim C., Esiri M., Evetts S. G., Rolinski M. et al. (2016). Alpha-synuclein RT-QuIC in the CSF of patients with alpha-synucleinopathies. Ann. Clin. Transl. Neurol. 3, 812-818. 10.1002/acn3.338
    1. Feneberg E., Steinacker P., Lehnert S., Schneider A., Walther P., Thal D. R., Linsenmeier M., Ludolph A. C. and Otto M. (2014). Limited role of free TDP-43 as a diagnostic tool in neurodegenerative diseases. Amyotroph. Lateral Scler. Frontotemporal. Degener. 15, 351-356. 10.3109/21678421.2014.905606
    1. Finnema S. J., Nabulsi N. B., Eid T., Detyniecki K., Lin S. F., Chen M. K., Dhaher R., Matuskey D., Baum E., Holden D. et al. (2016). Imaging synaptic density in the living human brain. Sci. Transl. Med. 8, 348ra96 10.1126/scitranslmed.aaf6667
    1. Fodero-Tavoletti M. T., Mulligan R. S., Okamura N., Furumoto S., Rowe C. C., Kudo Y., Masters C. L., Cappai R., Yanai K. and Villemagne V. L. (2009). In vitro characterisation of BF227 binding to alpha-synuclein/Lewy bodies. Eur. J. Pharmacol. 617, 54-58. 10.1016/j.ejphar.2009.06.042
    1. Galimberti D., Schoonenboom N., Scheltens P., Fenoglio C., Bouwman F., Venturelli E., Guidi I., Blankenstein M. A., Bresolin N. and Scarpini E. (2006a). Intrathecal chemokine synthesis in mild cognitive impairment and Alzheimer disease. Arch. Neurol. 63, 538-543. 10.1001/archneur.63.4.538
    1. Galimberti D., Schoonenboom N., Scheltens P., Fenoglio C., Venturelli E., Pijnenburg Y. A. L., Bresolin N. and Scarpini E. (2006b). Intrathecal chemokine levels in Alzheimer disease and frontotemporal lobar degeneration. Neurology 66, 146-147. 10.1212/01.wnl.0000191324.08289.9d
    1. Grundke-Iqbal I., Iqbal K., Tung Y. C., Quinlan M., Wisniewski H. M. and Binder L. I. (1986). Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc. Natl. Acad. Sci. USA 83, 4913-4917. 10.1073/pnas.83.13.4913
    1. Guerreiro R., Wojtas A., Bras J., Carrasquillo M., Rogaeva E., Majounie E., Cruchaga C., Sassi C., Kauwe J. S. K., Younkin S. et al. (2013). TREM2 variants in Alzheimer's disease. N. Engl. J. Med. 368, 117-127. 10.1056/NEJMoa1211851
    1. Hall S., Öhrfelt A., Constantinescu R., Andreasson U., Surova Y., Bostrom F., Nilsson C., Hakan W., Decraemer H., Nägga K. et al. (2012). Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. Arch. Neurol. 69, 1445-1452. 10.1001/archneurol.2012.1654
    1. Hansson O., Hall S., Öhrfelt A., Zetterberg H., Blennow K., Minthon L., Nägga K., Londos E., Varghese S., Majbour N. K. et al. (2014). Levels of cerebrospinal fluid alpha-synuclein oligomers are increased in Parkinson's disease with dementia and dementia with Lewy bodies compared to Alzheimer's disease. Alzheimers Res. Ther. 6, 25 10.1186/alzrt255
    1. Hellwig K., Kvartsberg H., Portelius E., Andreasson U., Oberstein T. J., Lewczuk P., Blennow K., Kornhuber J., Maler J. M., Zetterberg H. et al. (2015). Neurogranin and YKL-40: independent markers of synaptic degeneration and neuroinflammation in Alzheimer's disease. Alzheimers Res. Ther. 7, 74 10.1186/s13195-015-0161-y
    1. Herukka S.-K., Simonsen A. H., Andreasen N., Baldeiras I., Bjerke M., Blennow K., Engelborghs S., Frisoni G. B., Gabryelewicz T., Galluzzi S. et al. (2017). Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment. Alzheimers Dement. 13, 285-295. 10.1016/j.jalz.2016.09.009
    1. Heslegrave A., Heywood W., Paterson R., Magdalinou N., Svensson J., Johansson P., Öhrfelt A., Blennow K., Hardy J., Schott J. et al. (2016). Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer's disease. Mol. Neurodegener. 11, 3 10.1186/s13024-016-0071-x
    1. Hesse C., Rosengren L., Andreasen N., Davidsson P., Vanderstichele H., Vanmechelen E. and Blennow K. (2001). Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke. Neurosci. Lett. 297, 187-190. 10.1016/S0304-3940(00)01697-9
    1. Hong Z., Shi M., Chung K. A., Quinn J. F., Peskind E. R., Galasko D., Jankovic J., Zabetian C. P., Leverenz J. B., Baird G. et al. (2010). DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain 133, 713-726. 10.1093/brain/awq008
    1. Hyman B. T., Phelps C. H., Beach T. G., Bigio E. H., Cairns N. J., Carrillo M. C., Dickson D. W., Duyckaerts C., Frosch M. P., Masliah E. et al. (2012). National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement. 8, 1-13. 10.1016/j.jalz.2011.10.007
    1. Jack C. R. Jr. and Holtzman D. M. (2013). Biomarker modeling of Alzheimer's disease. Neuron 80, 1347-1358. 10.1016/j.neuron.2013.12.003
    1. James B. D., Wilson R. S., Boyle P. A., Trojanowski J. Q., Bennett D. A. and Schneider J. A. (2016). TDP-43 stage, mixed pathologies, and clinical Alzheimer's-type dementia. Brain 139, 2983-2993. 10.1093/brain/aww224
    1. Janelidze S., Stomrud E., Palmqvist S., Zetterberg H., van Westen D., Jeromin A., Song L., Hanlon D., Tan Hehir C. A., Baker D. et al. (2016). Plasma beta-amyloid in Alzheimer's disease and vascular disease. Sci. Rep. 6, 26801 10.1038/srep26801
    1. Jonsson T., Stefansson H., Steinberg S., Jonsdottir I., Jonsson P. V., Snaedal J., Bjornsson S., Huttenlocher J., Levey A. I., Lah J. J. et al. (2013). Variant of TREM2 associated with the risk of Alzheimer's disease. N. Engl. J. Med. 368, 107-116. 10.1056/NEJMoa1211103
    1. Kaneko N., Nakamura A., Washimi Y., Kato T., Sakurai T., Arahata Y., Bundo M., Takeda A., Niida S., Ito K. et al. (2014). Novel plasma biomarker surrogating cerebral amyloid deposition. Proc. Jpn. Acad. Ser. B Phys. Biol. Sci. 90, 353-364. 10.2183/pjab.90.353
    1. Kapaki E., Paraskevas G. P., Emmanouilidou E. and Vekrellis K. (2013). The diagnostic value of CSF alpha-synuclein in the differential diagnosis of dementia with Lewy bodies vs. normal subjects and patients with Alzheimer's disease. PLoS ONE 8, e81654 10.1371/journal.pone.0081654
    1. Kester M. I., Teunissen C. E., Crimmins D. L., Herries E. M., Ladenson J. H., Scheltens P., van der Flier W. M., Morris J. C., Holtzman D. M. and Fagan A. M. (2015). Neurogranin as a cerebrospinal fluid biomarker for synaptic loss in symptomatic Alzheimer disease. JAMA Neurol. 72, 1275-1280. 10.1001/jamaneurol.2015.1867
    1. Kikuchi A., Takeda A., Okamura N., Tashiro M., Hasegawa T., Furumoto S., Kobayashi M., Sugeno N., Baba T., Miki Y. et al. (2010). In vivo visualization of alpha-synuclein deposition by carbon-11-labelled 2-[2-(2-dimethylaminothiazol-5-yl)ethenyl]-6-[2-(fluoro)ethoxy]benzoxazole positron emission tomography in multiple system atrophy. Brain 133, 1772-1778. 10.1093/brain/awq091
    1. Klunk W. E., Engler H., Nordberg A., Wang Y., Blomqvist G., Holt D. P., Bergström M., Savitcheva I., Huang G.-F., Estrada S. et al. (2004). Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann. Neurol. 55, 306-319. 10.1002/ana.20009
    1. Kolb H. C. and Andres J. I. (2017). Tau positron emission tomography imaging. Cold Spring Harb. Perspect. Biol. 9, a023721 10.1101/cshperspect.a023721
    1. Kovacs G. G. (2016). Molecular pathological classification of neurodegenerative diseases: turning towards precision medicine. Int. J. Mol. Sci. 17, 189 10.3390/ijms17020189
    1. Kuhlmann J., Andreasson U., Pannee J., Bjerke M., Portelius E., Leinenbach A., Bittner T., Korecka M., Jenkins R. G., Vanderstichele H. et al. (2016). CSF Abeta1-42 - an excellent but complicated Alzheimer's biomarker - a route to standardisation. Clin. Chim. Acta 467, 27-33. 10.1016/j.cca.2016.05.014
    1. Kvartsberg H., Duits F. H., Ingelsson M., Andreasen N., Öhrfelt A., Andersson K., Brinkmalm G., Lannfelt L., Minthon L., Hansson O. et al. (2015a). Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease. Alzheimers Dement. 11, 1180-1190. 10.1016/j.jalz.2014.10.009
    1. Kvartsberg H., Portelius E., Andreasson U., Brinkmalm G., Hellwig K., Lelental N., Kornhuber J., Hansson O., Minthon L., Spitzer P. et al. (2015b). Characterization of the postsynaptic protein neurogranin in paired cerebrospinal fluid and plasma samples from Alzheimer's disease patients and healthy controls. Alzheimers Res. Ther. 7, 40 10.1186/s13195-015-0124-3
    1. Lagarde J., Sarazin M. and Bottlaender M. (2017). In vivo PET imaging of neuroinflammation in Alzheimer's disease. J. Neural. Transm. (Vienna) 125, 847-867. 10.1007/s00702-017-1731-x
    1. Landqvist Waldö M., Frizell Santillo A., Passant U., Zetterberg H., Rosengren L., Nilsson C. and Englund E. (2013). Cerebrospinal fluid neurofilament light chain protein levels in subtypes of frontotemporal dementia. BMC Neurol. 13, 54 10.1186/1471-2377-13-54
    1. Lashley T., Holton J. L., Gray E., Kirkham K., O'Sullivan S. S., Hilbig A., Wood N. W., Lees A. J. and Revesz T. (2008). Cortical alpha-synuclein load is associated with amyloid-beta plaque burden in a subset of Parkinson's disease patients. Acta Neuropathol. 115, 417-425. 10.1007/s00401-007-0336-0
    1. Lue L.-F., Schmitz C. T., Serrano G., Sue L. I., Beach T. G. and Walker D. G. (2015). TREM2 protein expression changes correlate with Alzheimer's disease neurodegenerative pathologies in post-mortem temporal cortices. Brain Pathol. 25, 469-480. 10.1111/bpa.12190
    1. Magdalinou N. K., Paterson R. W., Schott J. M., Fox N. C., Mummery C., Blennow K., Bhatia K., Morris H. R., Giunti P., Warner T. T. et al. (2015). A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes. J. Neurol. Neurosurg. Psychiatry 86, 1240-1247. 10.1136/jnnp-2014-309562
    1. Marquié M., Normandin M. D., Vanderburg C. R., Costantino I. M., Bien E. A., Rycyna L. G., Klunk W. E., Mathis C. A., Ikonomovic M. D., Debnath M. L. et al. (2015). Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Ann. Neurol. 78, 787-800. 10.1002/ana.24517
    1. Masters C. L., Simms G., Weinman N. A., Multhaup G., McDonald B. L. and Beyreuther K. (1985). Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc. Natl. Acad. Sci. USA 82, 4245-4249. 10.1073/pnas.82.12.4245
    1. Mattsson N., Tabatabaei S., Johansson P., Hansson O., Andreasson U., Månsson J.-E., Johansson J.-O., Olsson B., Wallin A., Svensson J. et al. (2011). Cerebrospinal fluid microglial markers in Alzheimer's disease: elevated chitotriosidase activity but lack of diagnostic utility. Neuromolecular Med. 13, 151-159. 10.1007/s12017-011-8147-9
    1. Mattsson N., Schott J. M., Hardy J., Turner M. R. and Zetterberg H. (2016a). Selective vulnerability in neurodegeneration: insights from clinical variants of Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 87, 1000-1004. 10.1136/jnnp-2015-311321
    1. Mattsson N., Zetterberg H., Janelidze S., Insel P. S., Andreasson U., Stomrud E., Palmqvist S., Baker D., Tan Hehir C. A., Jeromin A. et al. (2016b). Plasma tau in Alzheimer disease. Neurology 87, 1827-1835. 10.1212/WNL.0000000000003246
    1. Mattsson N., Schöll M., Strandberg O., Smith R., Palmqvist S., Insel P. S., Hägerström D., Ohlsson T., Zetterberg H., Jögi J. et al. (2017). (18)F-AV-1451 and CSF T-tau and P-tau as biomarkers in Alzheimer's disease. EMBO Mol. Med. 9, 1212-1223. 10.15252/emmm.201707809
    1. Mollenhauer B., El-Agnaf O. M. A., Marcus K., Trenkwalder C. and Schlossmacher M. G. (2010). Quantification of alpha-synuclein in cerebrospinal fluid as a biomarker candidate: review of the literature and considerations for future studies. Biomark. Med. 4, 683-699. 10.2217/bmm.10.90
    1. Mollenhauer B., Locascio J. J., Schulz-Schaeffer W., Sixel-Döring F., Trenkwalder C. and Schlossmacher M. G. (2011). alpha-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol. 10, 230-240. 10.1016/S1474-4422(11)70014-X
    1. Morbelli S. and Bauckneht M. (2018). Amyloid PET imaging: standardization and integration with other Alzheimer's disease biomarkers. Methods Mol. Biol. 1750, 203-212. 10.1007/978-1-4939-7704-8_13
    1. Nakamura A., Kaneko N., Villemagne V. L., Kato T., Doecke J., Doré V., Fowler C., Li Q.-X., Martins R., Rowe C. et al. (2018). High performance plasma amyloid-beta biomarkers for Alzheimer's disease. Nature 554, 249-254. 10.1038/nature25456
    1. Oeckl P., Metzger F., Nagl M., von Arnim C. A. F., Halbgebauer S., Steinacker P., Ludolph A. C. and Otto M. (2016). Alpha-, Beta-, and gamma-synuclein quantification in cerebrospinal fluid by multiple reaction monitoring reveals increased concentrations in Alzheimer's and Creutzfeldt-Jakob disease but no alteration in synucleinopathies. Mol. Cell. Proteomics 15, 3126-3138. 10.1074/mcp.M116.059915
    1. Öhrfelt A., Grognet P., Andreasen N., Wallin A., Vanmechelen E., Blennow K. and Zetterberg H. (2009). Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss? Neurosci. Lett. 450, 332-335. 10.1016/j.neulet.2008.11.015
    1. Öhrfelt A., Axelsson M., Malmeström C., Novakova L., Heslegrave A., Blennow K., Lycke J. and Zetterberg H. (2016). Soluble TREM-2 in cerebrospinal fluid from patients with multiple sclerosis treated with natalizumab or mitoxantrone. Mult. Scler. 22, 1587-1595. 10.1177/1352458515624558
    1. Olsson B., Hertze J., Lautner R., Zetterberg H., Nagga K., Hoglund K., Basun H., Annas P., Lannfelt L., Andreasen N. et al. (2013). Microglial markers are elevated in the prodromal phase of Alzheimer's disease and vascular dementia. J. Alzheimers Dis. 33, 45-53. 10.3233/JAD-2012-120787
    1. Olsson B., Lautner R., Andreasson U., Öhrfelt A., Portelius E., Bjerke M., Hölttä M., Rosén C., Olsson C., Strobel G. et al. (2016). CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. Lancet Neurol. 15, 673-684. 10.1016/S1474-4422(16)00070-3
    1. Ossenkoppele R., Schonhaut D. R., Schöll M., Lockhart S. N., Ayakta N., Baker S. L., O'Neil J. P., Janabi M., Lazaris A., Cantwell A. et al. (2016). Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease. Brain 139, 1551-1567. 10.1093/brain/aww027
    1. Ovod V., Ramsey K. N., Mawuenyega K. G., Bollinger J. G., Hicks T., Schneider T., Sullivan M., Paumier K., Holtzman D. M., Morris J. C. et al. (2017). Amyloid beta concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. Alzheimers Dement. 13, 841-849. 10.1016/j.jalz.2017.06.2266
    1. Payoux P. and Salabert A. S. (2017). New PET markers for the diagnosis of dementia. Curr. Opin. Neurol. 30, 606-616. 10.1097/WCO.0000000000000489
    1. Peluso M. J., Valcour V., Phanuphak N., Ananworanich J., Fletcher J. L. K., Chalermchai T., Krebs S. J., Robb M. L., Hellmuth J., Gisslén M. et al. (2017). Immediate initiation of cART is associated with lower levels of cerebrospinal fluid YKL-40, a marker of microglial activation, in HIV-1 infection. AIDS 31, 247-252. 10.1097/QAD.0000000000001314
    1. Piccio L., Deming Y., Del-Aguila J. L., Ghezzi L., Holtzman D. M., Fagan A. M., Fenoglio C., Galimberti D., Borroni B. and Cruchaga C. (2016). Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status. Acta Neuropathol. 131, 925-933. 10.1007/s00401-016-1533-5
    1. Portelius E., Zetterberg H., Skillbäck T., Törnqvist U., Andreasson U., Trojanowski J. Q., Weiner M. W., Shaw L. M., Mattsson N. and Blennow K. (2015). Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease. Brain 138, 3373-3385. 10.1093/brain/awv267
    1. Ramont L., Thoannes H., Volondat A., Chastang F., Millet M.-C. and Maquart F.-X. (2005). Effects of hemolysis and storage condition on neuron-specific enolase (NSE) in cerebrospinal fluid and serum: implications in clinical practice. Clin. Chem. Lab. Med. 43, 1215-1217. 10.1515/CCLM.2005.210
    1. Rathore S., Habes M., Iftikhar M. A., Shacklett A. and Davatzikos C. (2017). A review on neuroimaging-based classification studies and associated feature extraction methods for Alzheimer's disease and its prodromal stages. Neuroimage 155, 530-548. 10.1016/j.neuroimage.2017.03.057
    1. Represa A., Deloulme J. C., Sensenbrenner M., Ben-Ari Y. and Baudier J. (1990). Neurogranin: immunocytochemical localization of a brain-specific protein kinase C substrate. J. Neurosci. 10, 3782-3792. 10.1523/JNEUROSCI.10-12-03782.1990
    1. Riemenschneider M., Wagenpfeil S., Vanderstichele H., Otto M., Wiltfang J., Kretzschmar H., Vanmechelen E., Förstl H. and Kurz A. (2003). Phospho-tau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt-Jakob disease from other dementias. Mol. Psychiatry 8, 343-347. 10.1038/sj.mp.4001220
    1. Sander K., Lashley T., Gami P., Gendron T., Lythgoe M. F., Rohrer J. D., Schott J. M., Revesz T., Fox N. C. and Årstad E. (2016). Characterization of tau positron emission tomography tracer [18F]AV-1451 binding to postmortem tissue in Alzheimer's disease, primary tauopathies, and other dementias. Alzheimers Dement. 12, 1116-1124. 10.1016/j.jalz.2016.01.003
    1. Schmidt M. E., Chiao P., Klein G., Matthews D., Thurfjell L., Cole P. E., Margolin R., Landau S., Foster N. L., Mason N. S. et al. (2015). The influence of biological and technical factors on quantitative analysis of amyloid PET: points to consider and recommendations for controlling variability in longitudinal data. Alzheimers Dement. 11, 1050-1068. 10.1016/j.jalz.2014.09.004
    1. Schneider J. A., Arvanitakis Z., Leurgans S. E. and Bennett D. A. (2009). The neuropathology of probable Alzheimer disease and mild cognitive impairment. Ann. Neurol. 66, 200-208. 10.1002/ana.21706
    1. Schöll M., Lockhart S. N., Schonhaut D. R., O'Neil J. P., Janabi M., Ossenkoppele R., Baker S. L., Vogel J. W., Faria J., Schwimmer H. D. et al. (2016). PET imaging of Tau deposition in the aging human brain. Neuron 89, 971-982. 10.1016/j.neuron.2016.01.028
    1. Schott J. M. and Warren J. D. (2012). Alzheimer's disease: mimics and chameleons. Pract. Neurol. 12, 358-366. 10.1136/practneurol-2012-000315
    1. Selkoe D. J. (2002). Alzheimer's disease is a synaptic failure. Science 298, 789-791. 10.1126/science.1074069
    1. Seppala T. T., Nerg O., Koivisto A. M., Rummukainen J., Puli L., Zetterberg H., Pyykko O. T., Helisalmi S., Alafuzoff I., Hiltunen M. et al. (2012). CSF biomarkers for Alzheimer disease correlate with cortical brain biopsy findings. Neurology 78, 1568-1575. 10.1212/WNL.0b013e3182563bd0
    1. Shahnawaz M., Tokuda T., Waragai M., Mendez N., Ishii R., Trenkwalder C., Mollenhauer B. and Soto C. (2016). Development of a biochemical diagnosis of Parkinson disease by detection of alpha-Synuclein misfolded aggregates in cerebrospinal fluid. JAMA Neurol. 74, 163-172. 10.1001/jamaneurol.2016.4547
    1. Shi M., Kovac A., Korff A., Cook T. J., Ginghina C., Bullock K. M., Yang L., Stewart T., Zheng D., Aro P. et al. (2016). CNS tau efflux via exosomes is likely increased in Parkinson's disease but not in Alzheimer's disease. Alzheimers Dement. 12, 1125-1131. 10.1016/j.jalz.2016.04.003
    1. Simonsen A. H., Herukka S.-K., Andreasen N., Baldeiras I., Bjerke M., Blennow K., Engelborghs S., Frisoni G. B., Gabryelewicz T., Galluzzi S. et al. (2017). Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia. Alzheimers Dement. 13, 274-284. 10.1016/j.jalz.2016.09.008
    1. Sjogren M., Rosengren L., Minthon L., Davidsson P., Blennow K. and Wallin A. (2000). Cytoskeleton proteins in CSF distinguish frontotemporal dementia from AD. Neurology 54, 1960-1964. 10.1212/WNL.54.10.1960
    1. Skillback T., Farahmand B., Bartlett J. W., Rosen C., Mattsson N., Nagga K., Kilander L., Religa D., Wimo A., Winblad B. et al. (2014). CSF neurofilament light differs in neurodegenerative diseases and predicts severity and survival. Neurology 83, 1945-1953. 10.1212/WNL.0000000000001015
    1. Slaets S., Vanmechelen E., Le Bastard N., Decraemer H., Vandijck M., Martin J.-J., De Deyn P. P. and Engelborghs S. (2014). Increased CSF alpha-synuclein levels in Alzheimer's disease: correlation with tau levels. Alzheimers Dement. 10, S290-S298. 10.1016/j.jalz.2013.10.004
    1. Smailagic N., Vacante M., Hyde C., Martin S., Ukoumunne O. and Sachpekidis C. (2015). (1)(8)F-FDG PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst. Rev. 1, CD010632 10.1002/14651858.CD010632.pub2
    1. Steinacker P., Blennow K., Halbgebauer S., Shi S., Ruf V., Oeckl P., Giese A., Kuhle J., Slivarichova D., Zetterberg H. et al. (2016). Neurofilaments in blood and CSF for diagnosis and prediction of onset in Creutzfeldt-Jakob disease. Sci. Rep. 6, 38737 10.1038/srep38737
    1. Strimbu K. and Tavel J. A. (2010). What are biomarkers? Curr. Opin. HIV AIDS 5, 463-466. 10.1097/COH.0b013e32833ed177
    1. Suárez-Calvet M., Kleinberger G., Araque Caballero M. Á., Brendel M., Rominger A., Alcolea D., Fortea J., Lleó A., Blesa R., Gispert J. D. et al. (2016). sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer's disease and associate with neuronal injury markers. EMBO Mol. Med. 8, 466-476. 10.15252/emmm.201506123
    1. Takahashi K., Rochford C. D. P. and Neumann H. (2005). Clearance of apoptotic neurons without inflammation by microglial triggering receptor expressed on myeloid cells-2. J. Exp. Med. 201, 647-657. 10.1084/jem.20041611
    1. Tarawneh R., D'Angelo G., Crimmins D., Herries E., Griest T., Fagan A. M., Zipfel G. J., Ladenson J. H., Morris J. C. and Holtzman D. M. (2016). Diagnostic and prognostic utility of the synaptic marker neurogranin in Alzheimer disease. JAMA Neurol. 73, 561-571. 10.1001/jamaneurol.2016.0086
    1. Tateno F., Sakakibara R., Kawai T., Kishi M. and Murano T. (2012). Alpha-synuclein in the cerebrospinal fluid differentiates synucleinopathies (Parkinson Disease, dementia with Lewy bodies, multiple system atrophy) from Alzheimer disease. Alzheimer Dis. Assoc. Disord. 26, 213-216. 10.1097/WAD.0b013e31823899cc
    1. Thorsell A., Bjerke M., Gobom J., Brunhage E., Vanmechelen E., Andreasen N., Hansson O., Minthon L., Zetterberg H. and Blennow K. (2010). Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer's disease. Brain Res. 1362, 13-22. 10.1016/j.brainres.2010.09.073
    1. Tokuda T., Qureshi M. M., Ardah M. T., Varghese S., Shehab S. A. S., Kasai T., Ishigami N., Tamaoka A., Nakagawa M. and El-Agnaf O. M. A. (2010). Detection of elevated levels of alpha-synuclein oligomers in CSF from patients with Parkinson disease. Neurology 75, 1766-1772. 10.1212/WNL.0b013e3181fd613b
    1. Uchihara T. and Giasson B. I. (2016). Propagation of alpha-synuclein pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies. Acta Neuropathol. 131, 49-73. 10.1007/s00401-015-1485-1
    1. van Eijk J. J. J., van Everbroeck B., Abdo W. F., Kremer B. P. H. and Verbeek M. M. (2010). CSF neurofilament proteins levels are elevated in sporadic Creutzfeldt-Jakob disease. J. Alzheimers Dis. 21, 569-576. 10.3233/JAD-2010-090649
    1. Voyle N., Baker D., Burnham S. C., Covin A., Zhang Z., Sangurdekar D. P., Tan Hehir C. A., Bazenet C., Lovestone S., Kiddle S. et al. (2015). Blood protein markers of neocortical amyloid-beta burden: a candidate study using SOMAscan technology. J. Alzheimers Dis. 46, 947-961. 10.3233/JAD-150020
    1. Walker L. C. and Jucker M. (2015). Neurodegenerative diseases: expanding the prion concept. Annu. Rev. Neurosci. 38, 87-103. 10.1146/annurev-neuro-071714-033828
    1. Wallin A. K., Blennow K., Zetterberg H., Londos E., Minthon L. and Hansson O. (2010). CSF biomarkers predict a more malignant outcome in Alzheimer disease. Neurology 74, 1531-1537. 10.1212/WNL.0b013e3181dd4dd8
    1. Watabe-Rudolph M., Song Z., Lausser L., Schnack C., Begus-Nahrmann Y., Scheithauer M.-O., Rettinger G., Otto M., Tumani H., Thal D. R. et al. (2012). Chitinase enzyme activity in CSF is a powerful biomarker of Alzheimer disease. Neurology 78, 569-577. 10.1212/WNL.0b013e318247caa1
    1. Wellington H., Paterson R. W., Portelius E., Törnqvist U., Magdalinou N., Fox N. C., Blennow K., Schott J. M. and Zetterberg H. (2016). Increased CSF neurogranin concentration is specific to Alzheimer disease. Neurology 86, 829-835. 10.1212/WNL.0000000000002423
    1. Wennström M., Surova Y., Hall S., Nilsson C., Minthon L., Boström F., Hansson O. and Nielsen H. M. (2013). Low CSF levels of both alpha-synuclein and the alpha-synuclein cleaving enzyme neurosin in patients with synucleinopathy. PLoS ONE 8, e53250 10.1371/journal.pone.0053250
    1. Westwood S., Leoni E., Hye A., Lynham S., Khondoker M. R., Ashton N. J., Kiddle S. J., Baird A. L., Sainz-Fuertes R., Leung R. et al. (2016). Blood-based biomarker candidates of cerebral amyloid using PiB PET in non-demented elderly. J. Alzheimers Dis. 52, 561-572. 10.3233/JAD-151155
    1. Winblad B., Amouyel P., Andrieu S., Ballard C., Brayne C., Brodaty H., Cedazo-Minguez A., Dubois B., Edvardsson D., Feldman H. et al. (2016). Defeating Alzheimer's disease and other dementias: a priority for European science and society. Lancet Neurol. 15, 455-532. 10.1016/S1474-4422(16)00062-4
    1. Winston C. N., Goetzl E. J., Akers J. C., Carter B. S., Rockenstein E. M., Galasko D., Masliah E. and Rissman R. A. (2016). Prediction of conversion from mild cognitive impairment to dementia with neuronally derived blood exosome protein profile. Alzheimers Dement. 3, 63-72. 10.1016/j.dadm.2016.04.001
    1. Yin G. N., Jeon H., Lee S., Lee H. W., Cho J.-Y. and Suk K. (2009). Role of soluble CD14 in cerebrospinal fluid as a regulator of glial functions. J. Neurosci. Res. 87, 2578-2590. 10.1002/jnr.22081
    1. Zetterberg H. (2015). Plasma amyloid beta-quo vadis? Neurobiol. Aging 36, 2671-2673. 10.1016/j.neurobiolaging.2015.07.021
    1. Zetterberg H. (2016). Neurofilament light: a dynamic cross-disease fluid biomarker for neurodegeneration. Neuron 91, 1-3. 10.1016/j.neuron.2016.06.030
    1. Zetterberg H. (2017). Review: Tau in biofluids - relation to pathology, imaging and clinical features. Neuropathol. Appl. Neurobiol. 43, 194-199. 10.1111/nan.12378
    1. Zetterberg H., Wilson D., Andreasson U., Minthon L., Blennow K., Randall J. and Hansson O. (2013). Plasma tau levels in Alzheimer's disease. Alzheimers Res. Ther. 5, 9 10.1186/alzrt163
    1. Zetterberg H., Skillbäck T., Mattsson N., Trojanowski J. Q., Portelius E., Shaw L. M., Weiner M. W. and Blennow K. (2016). Association of cerebrospinal fluid neurofilament light concentration with Alzheimer disease progression. JAMA Neurol. 73, 60-67. 10.1001/jamaneurol.2015.3037

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel